study of hypofractionated radiotherapy alone in locally advanced nonsmall cell lung cancer patients

Conditions: Nonsmall Cell Lung Cancer, Stage II; Nonsmall Cell Lung Cancer Stage III

Summary: the purpose of this research study is to find out what effects (good or bad) may come from a new way of doing radiation therapy for lung cancer. this study is for patients who are not able to get surgery or chemotherapy with their radiation. the way of doing radiation therapy in this trial is called hypofractionated radiation therapy which is a standard approach, but this study allows the actual tumor to get an extra radiation dose while still protecting the organs that are near the tumor.

primary objective: • to determine the in-field control of hypofractionated radiotherapy consisting of 70 gy in 25 fractions without concurrent chemotherapy measured at two years after the first post- radiotherapy scan. secondary objective(s): * to determine the toxicity profile of thoracic hypofractionated radiotherapy consisting of 70 gy in 25 fractions as graded by common terminology criteria for adverse events (ctcae) version 5.0 * to determine proportion with local, regional, and distant progression at 1 and 2 years after the first post-radiotherapy scan, and compute progression-free and overall survival (progression-free survival and overall survival, respectively).

Eligibility criteria:
inclusion criteria: * histological confirmation of non-small cell lung cancer by either biopsy or cytology * american joint committee on cancer (ajcc) 8th edition stage ii-iii or ultracentral stage ib disease as determined by pet/ct and mri brain * ultracentral disease will be defined as edge of gross visible tumor within 1.0 cm of the proximal bronchial tree. * eastern cooperative oncology group (ecog) performance status of 0-3 * participant is not eligible for or has declined surgical resection or stereotactic body radiotherapy as determined by the treating physician * participant is not eligible for or has declined concurrent chemotherapy as determined by the treating physician * while investigators expect it to be an uncommon event, sequential use of systemic therapy after completion of radiation therapy is permissible if the participant's status improves such that they become eligible for such therapies, per the discretion of a multidisciplinary tumor board. * negative serum or urine pregnancy test within 2 weeks of the date of enrollment for women of child-bearing potential. * ability to understand and the willingness to sign an irb-approved informed consent document (either directly or via a legally authorized representative). exclusion criteria: * history of previous thoracic radiotherapy with the exception of prior radiotherapy for breast cancer without overlap of the fields with the cancer to be treated. * prior systemic therapy or surgery for the study cancer. * prior malignancy within the past two years except for non-melanoma skin cancer, prostate cancer, or any in-situ malignancy. * receipt of anti-angiogenic therapy, such as bevacizumab, within 6 months of enrollment. * pregnant women are excluded from this study because radiation therapy has known potential for teratogenic or abortifacient effects.